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NeuropsychiatricBackground and aim of the work: Systemic lupus erythematosus (SLE) is a multisystem autoimmune dis-
ease. Although eyes are seldom affected, this case report presents a 13-year-old Iranian girl with Raccoon
eyes and neuropsychiatric manifestations as an initial presentation of SLE.
Case presentation: The patient was admitted to the pediatric rheumatology inpatient, Mofid Children’s
Hospital, Tehran with swelling and ecchymosis around the eyes (Racoon eyes) as well as anorexia,
abdominal pain, weight loss, mood disorders and hallucinations. Complete blood count showed normo-
cytic, normochromic anemia, leukopenia, lymphopenia and thrombocytopenia. The C-reactive protein,
erythrocyte sedimentation rate, liver and renal functional tests, and urine analysis were normal. The
complement levels decreased, antinuclear antibody (ANA) and anti-double stranded DNA (anti-dsDNA)
tests were positive. Bilateral pleural effusion and mild pericardial effusion were seen. Bone marrow aspi-
ration showed mild hypocellularity without any evidence of malignancy. The diagnosis of neuropsychi-
atric SLE (NP-SLE) was held. She was treated by the pulse methyl prednisolone (30 mg/kg/d) and
intravenous cyclophosphamide (500 mg/m2), oral prednisolone and hydroxychloroquine. Her appetite
improved while hallucination and aggressive behavior decreased. Peri-orbital swelling and ecchymosis
decreased. After one year, her appetite became normal; mood disorders, panic, phobic attacks and hallu-
cinations were completely remedied. Swelling and ecchymosis around the eyes were eliminated. Oral
prednisolone 10 mgday and hydroxychloroquine (5 mg/kg/day) were continued.
Conclusion: SLE may present with Raccoon eyes. Rapid detection and treatment of the disease based on
clinical symptoms is critical for these patients. Prednisolone and cyclophosphamide are the best choice
for treatment of the disease in children.
 2020 Egyptian Society of Rheumatic Diseases. Publishing services provided by Elsevier B.V. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Systemic lupus erythematosus (SLE) is a complex, chronic, mul-
tisystem autoimmune disease affecting almost all body organs. The
prevalence of SLE varies in different parts of the world [1,2]. The
onset of clinical manifestations in SLE is variable and may have
implications on the disease course, remission and clinical relapse.
SLE is rarely associated with ocular involvement and may affect
fewer than 5% of patients during the first year. However, more than
30% of patientsmay eventually present ocular involvement over the
course of the disease or during the disease evolution. Lupusretinopathy is one of themost prevalent vision-threatening compli-
cations [3,4]. The initial presentation of SLE with neuropsychiatric
(NP) symptom is very rare. However, over the course of the disease,
22–95% of the patients finally develop NP symptoms such as head-
ache [5]. Gene polymorphisms of TNF-a and IL-6were implicated in
SLEwhile their serum levels tended to be related to the NPmanifes-
tations [6]. In this study, we reported a teenage girl with SLE who
was initially presented with Raccoon eyes (peri-orbital ecchymo-
sis), NP symptoms, and peripheral neuropathy.2. Case report
A 13-year-old Iranian girl, who presented with ecchymosis and
swelling signs around both eyes (peri-orbital), especially on the left
side, was admitted in Pediatric Rheumatologic ward, Mofid Chil-
dren,s Hospital, Shahid Beheshti University of Medical Sciences,
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the preceding 20 days and then gradually increased. After that, the
left eye had blurred vision and lessened the eye sight. The patient
was admitted to another hospital for a week with a diagnosis of
septal cellulitis and received intravenous clindamycin. The past
medical history of the patient revealed that she had anorexia,
abdominal pain and constipation about 18 months ago and was
treated with omeprazole as an endoscopic outpatient with gastri-
tis. Since then, the patient had mood disorder, panic attacks, and
sleep disorders. In the last few months, she had aggressive, phobic
behaviors and escaped from school. The patient had also motion
impairment in the right leg about 10 months ago. In the preceding
two months, she developed urinary incontinence. On examination,
her weight and height were 44 kg and 156 cm, respectively, with
body mass index (BMI) 18.1. There was ecchymosis and swelling
around both eyes, especially on the left (Raccoon eyes) (Fig. 1).
Painless ocular movements, visual acuity, ophthalmoscopic and
fundoscopic examinations were normal. There was right foot
inversion, reduced right leg deep tendon reflex and reduced pain
and heat sensation. The Babinski sign of the right foot was positive.
Her greater sister was a known case of SLE.
Complete blood count (CBC) showed leukopenia and mild lym-
phopenia. Other blood parameters or indices (e.g. serum elec-
trolytes, ammonia and lactate, coagulation tests, kidney and liver
function tests, and urine analysis) were normal. Erythrocyte sedi-
mentation rate (ESR), C-reactive protein (CRP), serum
immunoglobulins (Igs) and complement tests were normal.
Rheumatoid factor (RF), anti-nuclear antibody (ANA), anti -
double stranded DNA (anti-dsDNA) and anti-phospholipid anti-
bodies were negative. To rule-out neuroblastoma, Vanillin-
mandelic acid (VMA) was measured in 24-hour urine and was neg-
ative. Chest X-ray and echocardiography were normal. Orbital
computerized tomography (CT), total spinal magnetic resonance
imaging (MRI), brain MRI were normal. Electromyography (EMG)
and nerve conduction velocity (NCV) tests showed right foot
peripheral neuropathy. Serological tests were negative for human
immunodeficiency viruses (HIV), herpes simplex virus (HSV),
Epstein–Barr virus (EBV), Cytomegalovirus (CMV), brucella and
mycoplasma. Based on the historical, clinical, and laboratorial find-
ings, there was a probable diagnosis of SLE in view of the neurolog-
ical and hematological disorders and positive family history. She
was recommended to be followed, and oral gabapentin and
amitriptyline were prescribed for symptomatic treatment.
2.1. Second hospitalization
After eight months, the patient was re-admitted with chief
complaints of anorexia, abdominal pain, weight loss, mood disor-
ders and hallucinations, as well as increased ecchymosis and swel-
ling around the eyes. On physical examination her weight and
height were 35 kg and 157 cm respectively, (BMI 14.2). The patient
was pale with hepatosplenomegaly. The rest of clinical examina-Fig. 1. Ocular involvement of the patient before (tions did not change and remained constant compared to the pre-
ceding admission. The CBC showed normocytic, normochromic
anemia, leukopenia, lymphopenia and thrombocytopenia (pancy-
topenia). The patient had hypokalemia and hyponatremia. CRP,
ESR, coagulation tests, serum ammonia and lactate, liver and renal
functional tests, and urine analysis were normal. Complement
levels (CH50, C3, and C4) were clearly decreased, and ANA and
ds-DNA were positive. Chest x-ray showed bilateral pleural effu-
sion and echocardiography revealed mild pericardial effusion.
Her abdominal-pelvic CT revealed mild hepatosplenomegaly. Bone
marrow aspiration showed mild hypocellularity in all blood pat-
terns without any evidence of malignancy. Based on the American
College of Rheumatology and Systemic Lupus International Collab-
orating Clinics Classification Criteria for SLE [7], the diagnosis of
neuropsychiatric SLE (NP-SLE) was held: neurological and hemato-
logical manifestations, serositis, ANA and anti-dsDNA positive. She
was treated by pulse methyl prednisolone (30 mg/kg at a max of
1 g/dose) and intravenous cyclophosphamide (CYC) (500 mg/m2)
monthly for 6 months, then every 3 month, oral prednisolone
and hydroxychloroquine (HCQ).
2.2. Outcomes and follow-up
After treatment with first pulse methylprednisolone and CYC,
her appetite and energy improved and her hallucination and
aggressive behaviors decreased. Finally, the swelling and ecchymo-
sis around her eyes were beginning to decrease. Treatment with
oral prednisolone (2 mg/kg/day; max 60 mg/day) and HCQ
(5 mg/kg/day) was continued and the patient received pulse CYC
for 6 months. The oral prednisolone was tapered after 2 months
of treatment with decreasing 5 mg every two weeks until 20 mg
daily was reached at the 6th month of treatment. HCQ (5 mg/kg/-
day) continued during this period.
Subsequently, CYC pulse was infused (500 mg/m2) every month
for 6 months, then every 3 months along with the continuation of
oral medications. One year after the second admission and above
mentioned therapies, her appetite reached back to normal; her
weight and height increased to 47 kg and 160 cm, respectively.
Also all of her mood disorder symptoms, panic and phobic attacks,
and hallucinations were completely remedied. The antidepressant
and antipsychotic drugs were discontinued and the patient had no
problems at school. Swelling and ecchymosis around the eyes were
eliminated (Fig. 1). Oral prednisolone 10 mg daily and HCQ (5 mg/
kg/day) were continued.
3. Discussion
Systemic lupus erythematosus (SLE) is a heterogeneous autoim-
mune disease characterized by excessive inflammatory and
immune responses and tissue damage and involves various organs
and systems [8]. Measuring organ damage in SLE is important with
special concern to juvenile-onset patients to allow for designingleft: Racoon eye) and after (right) treatment.
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mize the development of irreversible damage [9]. Since about 20%
of cases are diagnosed before age 16, SLE in children under 5 is
really rare. There are multiple risk factors involved in its develop-
ment and sex is the first and the strongest disease determinant
with about 90% being females [1–4]. Estrogen plays an important
role in disease exacerbation stimulating B cells to produce autoan-
tibodies. C1q, C2, and C4 deficiencies are associated with disease
development. A family history of other autoimmune diseases and
a genetic background are also effective factors [10,11]. Further-
more, environmental factors (e.g. sunlight) and viruses (e.g. EBV)
raise the risk of SLE development [10].
Clinical symptoms of the juvenile patients are different from the
adults [9]. The most common primary clinical symptoms in chil-
dren with SLE include fever, fatigue, loss of appetite, musculoskele-
tal pain, hair loss, and painless oral ulcers [12]. LN is very common
in childhood-onset SLE and begins early in the disease course [13].
Neuropsychiatric manifestations of SLE may be associated with the
disease activity or could be misdiagnosed and treated as a mood
disorders, anxiety or psychosis. Musculoskeletal pain may also be
misdiagnosed in children as nonspecific growing pain for a long
time [12].
Ocular involvement of SLE is rare and could be orbital, peri-
orbital edema, keratoconjunctivitis sicca, episcleritis and retinopa-
thy [14]. Eye affection in SLE is very rare at the onset of the disease
and it is thus important to reveal [4,14]. Other ocular features in
SLE include involvement of the anterior and posterior segments,
proptosis, orbital pain, blurred vision, chemosis, enophthalmos,
and movement restrictions. Vasculitis is a potential key player in
SLE [15] and associated myositis may contribute to the eye affec-
tion and may be initially misdiagnosed as bacterial cellulitis [4].
Peri-orbital edema is seldom present at disease onset and may
occur in 4.8% throughout the course of the disease which may be
due to the increased vascular permeability, renal involvement, sec-
ondary angioedema, and mucin substitution in the skin [4,16]. Rac-
coon eyes in our patient may be due to increased vascular
permeability. Ocular involvement in SLE should be treated
promptly with systemic corticosteroids [4,14].
Neuropsychiatric lupus is rare in children at the onset of the
disease and is an indication of severity [17]. In spite of its contro-
versy in children’s NP-SLE, pulse CYC still seems to be an alterna-
tive of choice [17,18]. The diagnosis of SLE in a patient with
initial ocular involvement is a clinical challenge [4]. Raccoon eyes
may be caused by trauma to the surrounding eye or soft tissue
around it, fracture of the skull, malignancies, amyloidosis, rhino-
plasty or severe and prolonged intravenous pressure following
long-term coughing or sneezing [19,20].
Diagnosis of SLE with initial NP manifestations is a hindrance
issue for a physician with an old hand at clinical problems and is
delayed in many cases [17]. However, it is necessary to rapidly
diagnose and treat SLE with rare symptoms such as ocular and
NP to control the disease promptly and prevent further damage
and progress [4,17].
In conclusion, ocular involvement in the form of Racoon eyes
could be the initial presentation in juvenile SLE. Neuropsychiatric
manifestations could be associated with the eye affection at the
disease onset. Prompt diagnosis and management of the disease
is critical for these patients. Prednisolone and cyclophosphamide
are effective treatment options.Declaration of Competing Interest
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